nach oben

International Journal of Clinical Oncology

Erschienen in:

14.11.2015 | Review Article

Tumor hypoxia: a new PET imaging biomarker in clinical oncology

verfasst von: Nagara Tamaki, Kenji Hirata

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Tumor hypoxia is associated with tumor progression and resistance to various treatments. Noninvasive imaging using positron emission tomography (PET) and F-18-labeled fluoromisonidazole (FMISO) was recently introduced in order to define and quantify tumor hypoxia. The FMISO uptake was closely correlated with pimonidazole immunohistochemistry and hypoxia-inducible factor 1 expression in basic studies. Tumor hypoxia in head and neck cancers and other tumors in a clinical setting may also indicate resistance to radiation and/or chemotherapy. Hypoxic imaging may thus play a new and important role for suitable radiation planning, including dose escalation and dose reduction based on the image findings. Such radiation-dose painting based on the findings of hypoxia may require high-performance PET imaging to provide high target-to-background ratio images and an optimal quantitative parameter to define the hypoxic region. A multicenter prospective study using data from a large number of patients is also warranted to test the clinical value of hypoxic imaging.

Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10:695–712CrossRefPubMed

Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967–975. doi:10.1038/nrc2540 CrossRefPubMedPubMedCentral

Teicher BA (1995) Angiogenesis and cancer metastases: therapeutic approaches. Crit Rev Oncol Hematol 20:9–39CrossRefPubMed

Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL et al (2015) Imaging tumour hypoxia with positron emission tomography. Br J Cancer 112:238–250. doi:10.1038/bjc.2014.610 CrossRefPubMed

Semenza GL (2004) Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 19:176–182. doi:10.1152/physiol.00001.2004 CrossRefPubMed

Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129:465–472. doi:10.1016/j.cell.2007.04.019 CrossRefPubMedPubMedCentral

Jubb AM, Buffa FM, Harris AL (2010) Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 14:18–29. doi:10.1111/j.1582-4934.2009.00944.x CrossRefPubMed

Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40. doi:10.1634/theoncologist.9-90005-31 CrossRefPubMed

Cipolleschi MG, Dello Sbarba P, Olivotto M (1993) The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 82:2031–2037PubMed

10.

Huntly BJ, Gilliland DG (2005) Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5:311–321. doi:10.1038/nrc1592 CrossRefPubMed

11.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111. doi:10.1038/35102167 CrossRefPubMed

12.

Sundar SJ, Hsieh JK, Manjila S, Lathia JD, Sloan A (2014) The role of cancer stem cells in glioblastoma. Neurosurg Focus 37:E6. doi:10.3171/2014.9.FOCUS14494 CrossRefPubMed

13.

Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL (2014) Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA 111:E5429–E5438. doi:10.1073/pnas.1421438111 CrossRefPubMedPubMedCentral

14.

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMed

15.

Lartigau E, Lusinchi A, Weeger P, Wibault P, Luboinski B, Eschwege F et al (1998) Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer 34:856–861CrossRefPubMed

16.

Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F et al (1999) Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44:749–754CrossRefPubMed

17.

Doll CM, Milosevic M, Pintilie M, Hill RP, Fyles AW (2003) Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients. Int J Radiat Oncol Biol Phys 55:1239–1246CrossRefPubMed

18.

Raleigh JA, Dewhirst MW, Thrall DE (1996) Measuring tumor hypoxia. Semin Radiat Oncol 6:37–45. doi:10.1053/SRAO0060037 CrossRefPubMed

19.

Mendichovszky I, Jackson A (2011) Imaging hypoxia in gliomas. Br J Radiol 842:145–158. doi:10.1259/bjr/82292521 CrossRef

20.

Chia K, Fleming IN, Blower PJ (2012) Hypoxia imaging with PET: which tracers and why? Nucl Med Commun 33:217–222. doi:10.1097/MNM.0b013e32834eacb7 CrossRefPubMed

21.

Piert M (2009) Hypoxia imaging. In: Wahl RL (ed) Principles and practice of PET and PET/CT. 2nd ed: Lippincott Williams & Wilkins, Philadelphia, pp 464–471

22.

Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R et al (2002) Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J Nucl Med 43:1557–1569PubMed

23.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ (2001) Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 42:655–661PubMed

24.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ (2003) Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55:1233–1238CrossRefPubMed

25.

O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S et al (2005) Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61:1493–1502. doi:10.1016/j.ijrobp.2004.12.057 CrossRefPubMed

26.

Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ (1986) Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Radiat Appl Instrum Part A, Appl Radiat Isot 37:599–605CrossRef

27.

McClelland RA (1990) Molecualr interactions and biological effects of the products of reduction of nitroimidazoles. In: Adams GE, Breccia A, Fiedlen EN (eds) NATO advanced research workshop on selective activation of drugs by redox processes. New York Plenum Press, Plattsburgh, pp 125–136CrossRef

28.

Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA (1989) A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 30:343–350PubMed

29.

Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P et al (1999) Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 26:95–109CrossRefPubMed

30.

Troost EG, Laverman P, Philippens ME, Lok J, van der Kogel AJ, Oyen WJ et al (2008) Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 35:1803–1811. doi:10.1007/s00259-008-0772-7 CrossRefPubMed

31.

Fatema CN, Zhao S, Zhao Y, Yu W, Nishijima K, Yasuda K et al (2014) Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. BMC Cancer 14:692. doi:10.1186/1471-2407-14-692 CrossRefPubMedPubMedCentral

32.

Cheng X, Bayer C, Maftei CA, Astner ST, Vaupel P, Ziegler SI et al (2014) Preclinical evaluation of parametric image reconstruction of [18F]FMISO PET: correlation with ex vivo immunohistochemistry. Phys Med Biol 59:347–362. doi:10.1088/0031-9155/59/2/347 CrossRefPubMed

33.

Hatano T, Zhao S, Zhao Y, Nishijima K, Kuno N, Hanzawa H et al (2013) Biological characteristics of intratumoral [F-18]fluoromisonidazole distribution in a rodent model of glioma. Int J Oncol 42:823–830. doi:10.3892/ijo.2013.1781 PubMedPubMedCentral

34.

Oehler C, O’Donoghue JA, Russell J, Zanzonico P, Lorenzen S, Ling CC et al (2011) 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med 52:437–444. doi:10.2967/jnumed.110.081372 CrossRefPubMedPubMedCentral

35.

Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K et al (2012) Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 41:1593–1600. doi:10.3892/ijo.2012.1624 PubMedPubMedCentral

36.

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P et al (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18–24. doi:10.1016/j.radonc.2005.06.038 CrossRefPubMed

37.

Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J et al (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12:5435–5441. doi:10.1158/1078-0432.CCR-05-1773 CrossRefPubMedPubMedCentral

38.

Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G et al (2005) Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46:253–260PubMed

39.

Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y et al (2011) 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 25:625–633. doi:10.1007/s12149-011-0508-9 CrossRefPubMed

40.

Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M et al (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79–87. doi:10.1200/JCO.2005.01.072 CrossRefPubMed

41.

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. doi:10.1038/nrc1187 CrossRefPubMed

42.

Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K et al (2012) Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 3:783. doi:10.1038/ncomms1786 CrossRefPubMedPubMedCentral

43.

Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T et al (2013) 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma. J Nucl Med 54:1060–1065. doi:10.2967/jnumed.112.114355 CrossRefPubMed

44.

Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J et al (2008) The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 70:1219–1228. doi:10.1016/j.ijrobp.2007.09.050 CrossRefPubMedPubMedCentral

45.

Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S (2009) Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 50:1020–1027. doi:10.2967/jnumed.109.062638 CrossRefPubMed

46.

Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S et al (2008) Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 70:2–13. doi:10.1016/j.ijrobp.2007.06.039 CrossRefPubMed

47.

Vaupel P, Harrison L (2004) Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl. 5):4–9. doi:10.1634/theoncologist.9-90005-4 CrossRefPubMed

48.

Monnich D, Troost EG, Kaanders JH, Oyen WJ, Alber M, Thorwarth D (2012) Modelling and simulation of the influence of acute and chronic hypoxia on [18F]fluoromisonidazole PET imaging. Phys Med Biol 57:1675–1684. doi:10.1088/0031-9155/57/6/1675 CrossRefPubMed

49.

Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE et al (2008) Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70:235–242. doi:10.1016/j.ijrobp.2007.08.036 CrossRefPubMedPubMedCentral

50.

Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P et al (2004) pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 180:616–622. doi:10.1007/s00066-004-1229-y CrossRefPubMed

51.

Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K et al (2013) High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 54:201–207. doi:10.2967/jnumed.112.109330 CrossRefPubMed

52.

Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M (2006) Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80:151–156. doi:10.1016/j.radonc.2006.07.033 CrossRefPubMed

53.

Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS (1987) Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 28:68–75PubMed

54.

Morimoto Y, Ueno Y, Takeuchi W, Kojima S, Matsuzaki K, Ishitsu T et al (2011) Development of a 3D brain PET scanner using CdTe semiconductor detectors and its first clinical application. IEEE Trans Nucl Sci 58:2181–2189. doi:10.1109/Tns.2011.2146790 CrossRef

55.

Shiga T, Morimoto Y, Kubo N, Katoh N, Katoh C, Takeuchi W et al (2009) A new PET scanner with semiconductor detectors enables better identification of intratumoral inhomogeneity. J Nucl Med 50:148–155. doi:10.2967/jnumed.108.054833 CrossRefPubMed

56.

Yasuda K, Onimaru R, Okamoto S, Shiga T, Katoh N, Tsuchiya K et al (2013) [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 85:142–147. doi:10.1016/j.ijrobp.2012.03.029 CrossRefPubMed

57.

Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M et al (2014) Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging 41:2031–2041. doi:10.1007/s00259-014-2810-y CrossRefPubMed

58.

Tachibana I, Nishimura Y, Shibata T, Kanamori S, Nakamatsu K, Koike R et al (2013) A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. J Radiat Res 54:1078–1084. doi:10.1093/jrr/rrt033 CrossRefPubMedPubMedCentral

59.

Servagi-Vernat S, Differding S, Hanin FX, Labar D, Bol A, Lee JA et al (2014) A prospective clinical study of (1)(8)F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging 41:1544–1552. doi:10.1007/s00259-014-2730-x CrossRefPubMed

60.

Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H et al (2012) (18)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging 39:760–770. doi:10.1007/s00259-011-2037-0 CrossRefPubMed

61.

Yamamoto Y, Maeda Y, Kawai N, Kudomi N, Aga F, Ono Y et al (2012) Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl Med Commun 33:621–625. doi:10.1097/MNM.0b013e3283529984 CrossRefPubMed

62.

Kawai N, Maeda Y, Kudomi N, Miyake K, Okada M, Yamamoto Y et al (2011) Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 38:441–450. doi:10.1007/s00259-010-1645-4 CrossRefPubMed

63.

Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC Jr et al (2009) Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 69:4502–4509. doi:10.1158/0008-5472.CAN-08-3884 CrossRefPubMedPubMedCentral

64.

Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG et al (2008) Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 14:2623–2630. doi:10.1158/1078-0432.CCR-07-4995 CrossRefPubMedPubMedCentral

65.

Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A et al (2006) Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47:410–418

66.

Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R et al (2014) Correlation between (1)(8)F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging 41:1870–1878. doi:10.1007/s00259-014-2776-9 CrossRefPubMed

67.

Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M et al (2006) [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6:51. doi:10.1186/1471-2407-6-51 CrossRefPubMedPubMedCentral

68.

Li L, Hu M, Zhu H, Zhao W, Yang G, Yu J (2010) Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer 11:335–340. doi:10.3816/CLC.2010.n.042 CrossRefPubMed

69.

Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L et al (2013) Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3′-deoxy-3′-18F-fluorothymidine PET images in lung cancer. J Nucl Med 54:1543–1550. doi:10.2967/jnumed.112.118083 CrossRefPubMed

70.

Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I et al (2011) Simultaneous positron emission tomography (PET) assessment of metabolism with (1)(8)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (1)(8)F-fluoro-thymidine (FLT), and hypoxia with (1)(8)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 98:109–116. doi:10.1016/j.radonc.2010.10.011 CrossRefPubMed

71.

Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT et al (2006) Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 47:1921–1926PubMed

72.

Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM et al (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33:391–398. doi:10.1016/0360-3016(95)00170-4 CrossRefPubMed

73.

Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X et al (2013) 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med 54:333–340. doi:10.2967/jnumed.112.111963 CrossRefPubMed

74.

Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID et al (2005) Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 96:540–546. doi:10.1111/j.1464-410X.2005.05681.x CrossRefPubMed

75.

Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC et al (2009) Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 75:101–108. doi:10.1016/j.ijrobp.2008.10.049 CrossRefPubMedPubMedCentral

76.

DeLaney TF (2007) Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center. Technol Cancer Res Treat 6:61–66CrossRefPubMed

Titel: Tumor hypoxia: a new PET imaging biomarker in clinical oncology
verfasst von: Nagara Tamaki
Kenji Hirata
Publikationsdatum: 14.11.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0920-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Tumor hypoxia: a new PET imaging biomarker in clinical oncology

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy

Erratum to: UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer

Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Erratum to: UDP-glucuronosyltransferase 1A16 and 28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer